INSM logo Insmed : INSM

INSM

Stock Data

$159.74

Change up

$0.47 (0.30%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Insmed Inc is a biopharmaceutical firm focused on developing and marketing treatments for patients with serious and rare diseases globally. Its flagship product, ARIKAYCE, targets Mycobacterium avium complex lung disease in adults. The company is also working on Brensocatib for bronchiectasis and other diseases, and Treprostinil Palmitil Inhalation Powder for certain types of pulmonary hypertension. Founded in 1988, Insmed is based in Bridgewater, New Jersey, serving patients in the US, Europe, Japan, and beyond.

All Insmed Articles

7 Articles

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.